Summary
Hematology Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics Tests Analysis and Forecast Model therapeutic area.
Hematology Testing is used for a wide range of indications, with anemia, surgery, and pregnancy being responsible for the majority of test volumes. While both laboratory and point-of-care (POC) devices exist, laboratory-based assays represent the primary hematology testing method. Hematology market will continue to be dominated by lab testing within the forecast period with nominal growth in POC tests. Advantages of laboratory tests include lower ASP, greater perceived reliability of results, and the clinical importance of multiple parameters being readily available. POC devices provide capacity for quicker diagnoses and are useful in emergency settings, rural or remote regions, and for screening whole blood or source plasma donors.
Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model
Currently marketed Hematology Tests and evolving competitive landscape -
- Insightful review of the key industry trends.
- Annualized total Hematology Tests market revenue by segment and market outlooks from 2015-2028.
- Granular data on total procedures, units, average selling prices and market values by segment.
Global, Regional and Country level market specific insights -
- Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market.
- SWOT analysis for Hematology Tests market.
- Competitive dynamics insights and trends provided for Hematology Tests market.
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
- Country specific overview of the healthcare system.
- Country specific reimbursement policies.
- Country specific medtech regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Sysmex Corp, Roche Diagnostics International Ltd, Danaher Corporation (Radiometer Medical ApS), Beckman Coulter Inc, Abbott Laboratories, Horiba Ltd, EKF Diagnostics Holdings Plc, Thermo Fisher Scientific Inc, Siemens AG
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.
Scope
This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
- CMO executives who must have deep understanding of the Hematology Test marketplace to make strategic planning and investment decisions.
- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
- Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.
Reasons to buy
The model will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving Hematology Tests market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Hematology Tests market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track device sales in the global and country-specific Hematology Tests market from 2015-2028.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Companies Mentioned
Sysmex Corp
Roche Diagnostics International Ltd
Danaher Corporation (Radiometer Medical ApS)
Beckman Coulter Inc
Abbott Laboratories
Horiba Ltd
EKF Diagnostics Holdings Plc
Thermo Fisher Scientific Inc
Siemens AG
